16S rRNA methylase-producing Gram-negative bacteria are highly resistant to all clinically important aminoglycosides. We analyzed clinical strains of 16S rRNA methylase-producing Acinetobactor baumannii and Pseudomonas aeruginosa obtained from clinical isolates in medical settings in Vietnam.
Methods
From 2008 to 2011, 101 clinical strains of A. baumannii and 15 of P. aeruginosa were isolated from patients in intensive care units (ICUs) in two medical settings in Vietnam. Antimicrobial susceptibilities were determined using the microdilution method and epidemiological analysis was performed by pulsed-field gel electrophoresis and MLST. Genes encoding the 16S rRNA methylases, OXAs and CTX-Ms were analyzed by PCR and sequence analysis.
Results
16S rRNA methylase-producing Gram-negative pathogens were detected in two hospitals in Vietnam. Of the 101 clinical isolates of A. baumannii and the 15 of P. aeruginosa isolated from two ICUs in these hospitals, 72 (71.3%) were highly resistant to amikacin, arbekacin and gentamicin, with MICs greater than 1,024 mg/L. The 16S rRNA methylases ArmA and RmtB were produced by 61 and 9 isolates of A. baumannii, respectively, and RmtB was produced by 2 isolates of P. aeruginosa. Moreover, 52 of the A. baumannii isolates producing 16S rRNA methylases harbored both blaOXA-23-like and blaOXA-51-like genes. Most A. baumannii isolates producing 16S rRNA methylase obtained in hospital A in Hanoi were ST91 and ST231, whereas most from hospital B in Ho Chi Minh City were ST136, ST195, and ST254.
The two P. aeruginosa isolates harboring rmtB showed different patterns on PFGE, one each corresponding to ST217 and ST313.
Conclusions
Gram-negative bacteria producing the 16S rRNA methylases ArmA and RmtB are emerging in medical settings in Vietnam. A. baumannii isolates in northern and southern regions of Vietnam may be of different lineages.
The online version of this article (doi:10.1186/1471-2334-13-251) contains supplementary material, which is available to authorized users.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TT: Performed PCR and sequencing, analyzed data and drafted the manuscript. TMA: Performed MLST analyses. YK, NO, NT and TAT: Performed epidemiological analysis at BMH. NVH, NGB and NQA: Designed protocols and supervised this study at BMH. DMP, TTTN and PHT: Performed clinical bacterial analyses. PTX: Performed epidemiological analysis at CRH. LTAT and NTS: Designed protocols and supervised this study at CRH. TK: Designed protocols and supervised this study. All authors read and approved the final version manuscript.
Background
Aminoglycosides widely used to treat infectious diseases caused by Gram-negative bacteria have a high affinity for the 16S rRNA of the bacterial 30S ribosome and block protein synthesis [1]. Enzymatic modification [1] and the methylation of 16S rRNA makes these bacteria highly resistant to all clinically important aminoglycosides [2]. In 2003, clinical isolates of highly aminoglycoside-resistant Gram-negative bacteria producing16S rRNA methylase were identified in France [3] and Japan [4]. Since then, 16S rRNA methylase-producing Gram-negative bacteria have been isolated in other parts of the world, including Asian countries such as Afghanistan, Bangladesh, China, Hong Kong, India, Japan, Korea, Oman and Pakistan [5]. To date, however, there have been no reports of these isolates from South-East Asian countries, including Vietnam.
Since 2003, eight plasmid-associated 16S rRNA methylase genes, armA, rmtA, rmtB, rmtC, rmtD, rmtE, rmtF and npmA, have been identified in clinical and veterinary isolates from various geographic areas, including East Asia, Europe and the Americas, since 2003 [5, 6].
Anzeige
Methods
Bacterial strains
From 2008 to 2011, 50 clinical strains of A. baumannii and 15 of P. aeruginosa were isolated from patients in an ICU in hospital A in Hanoi, Vietnam; and 51 strains of A. baumannii were isolated from patients in an ICU in hospital B in Ho Chi Minh City, Vietnam. Of the 101 A. baumannii strains isolated, 98 were from patients’ respiratory tracts and 3 from blood. Of the 15 P. aeruginosa strains, 14 were from respiratory tracts and 1 from pus. Most patients were on ventilators, and the samples were mostly aspirates from ventilation tubes. All clinical isolates used in this study were obtained during standard patient care.
Antimicrobial susceptibility and pulsed-field gel electrophoresis (PFGE)
MICs of all bacteria to amikacin (Sigma-Aldrich, St. Louis, MO), arbekacin (Meiji Seika Pharma Co., Tokyo, Japan), aztreonam (Eizai, Tokyo, Japan), ceftadizime (Sigma-Aldrich), ciprofloxacin (Daiichi Pharmaceutical Co, Tokyo, Japan), colistin (Sigma-Aldrich), gentamicin (Nacalai Tesque, Kyoto, Japan), imipenem (Banyu Pharmaceutical Co, Tokyo, Japan), meropenem (Sumitomo Pharmaceutical Co., Osaka, Japan), piperacillin (Sigma-Aldrich) and pipiracillin/tazobactam (Toyama Chemical Co., Tokyo, Japan) were determined using the microdilution method, according to the guidelines of the Clinical and Laboratory Standards Institute (M07-A9). A. baumannii DNA was digested with the restriction enzyme ApaI and P. aeruginosa DNA was digested with SpeI, followed by pulsed-field gel electrophoresis (PFGE). PFGE analysis was performed as described previously [7]. Fingerprinting patterns were analyzed by the unweighted-pair-group method using Molecular Analyst Fingerprinting Plus software (Bio-Rad Laboratories, Hercules, CA, USA) to create an average linkage-based dendrogram.
Multilocus sequence typing (MLST)
MLST of 16S rRNA methylase-producing pathogens was performed according to the protocols described on the A. baumannii (http://pubmlst.org/abaumannii/) and P. aeruginosa (http://pubmlst.org/paeruginosa/) MLST Database websites. Seven chromosomal genes were PCR amplified and sequenced, with their nucleotide sequences compared with the sequences submitted to the MLST database to determine allele numbers and STs.
Detection of aminoglycoside-resistant genes
PCR with 16S rRNA methylase gene specific primers [2, 8, 9] was performed to detect the armA, rmtA, rmtB, rmtC, rmtD, rmt E and npmA genes. All PCR amplicons were sequenced using an ABI PRISM 3130 sequencer (Applied Biosystems, Foster City, CA, USA).
Anzeige
Whole genomes of methylase-negative A. baumannii and P. aeruginosa, which had MICs 128 mg/L to amikacin, 32 mg/L to arbekacin and 128 mg/L to gentamicin, were extracted by DNeasy Blood & Tissue kit (QIAGEN, Tokyo, Japan) and sequenced by MiSeq (Illumina, San Diego, CA). The sequence data were used to confirm aminoglycoside-resistant genes.
Detection of OXAs and CTX-Ms encoding genes
The presence of blaOXA-23-like, blaOXA-24-like, blaOXA-51-like, blaOXA-58-like and blaCTX-Ms in 16S rRNA methylase-producing isolates were investigated by PCR [10, 11].
Determination of the genetic environment surrounding rmtB
A draft genome sequence of an isolate of A. baumannii, NCGM36, harboring rmtB was determined using the GS Junior System (Roche Diagnostics K.K, Tokyo).
Ethical approval
This study was approved in 2007 by Ministry of Health, Bach Mai Hospital (Memorandum of agreement for the collaborative research project on epidemiology of nosocomial infections at the Bach Mai Hospital) and in 2011 by Cho Ray Hospital (approval number: 1644/QD-BVCR), and by the Biosafety Committee, National Center for Global Health and Medicine (approval number: 23-M-49).
Results
Antimicrobial susceptibility and aminoglycoside-resistant genes
The MICs at which 50% and 90% of the 101 A. baumannii and 15 P. aeruginosa isolates were inhibited (MIC50 and MIC90, respectively) were determined (Table 1). Seventy of the 101 A. baumannii isolates (71.3%) had MICs >1,024 mg/L to all aminoglycosides tested, including amikacin, arbekacin and gentamicin. All 70 isolates had 16S rRNA methylases, with 61 having armA and the remaining 9 having rmtB (Figure 1). The remaining 31 isolates had MICs ≤128 mg/L to amikacin, ≤32 mg/L to arbekacin and ≤128 mg/L to gentamicin and no methylase genes. Whole genome sequencing of 2 methylase-negative isolates showing relative resistance to aminoglycosides revealed that one had aac(6’)-IIb and aadB and that the other had aac(6’)-IIb and aadA2.
Table 1
MIC50 and MIC90 values and percent antimicrobial resistance forA. baumanniiandP. aeruginosaclinical isolates
Antimicrobial agent
A. baumannii(n = 101)
P. aeruginosa(n = 15)
Breakpoint forresistancea(mg/L)
%Resistance
Range(mg/L)
MIC50(mg/L)
MIC90(mg/L)
Breakpoint forresistancea(mg/L)
%Resistance
Range(mg/L)
MIC50(mg/L)
MIC90(mg/L)
Amikacin
≥64
85
<2- > 1024
>1024
>1024
≥64
60
<2- > 1024
64
>1024
Arbekacin
-
-
<2- > 1024
>1024
>1024
-
-
2- > 1024
2
>1024
Aztreonam
-
-
<2- > 256
128
>256
≥32
46
4- > 256
16
>256
Ceftazidime
≥32
55
<4- > 512
>512
>512
≥32
46
<4- > 512
16
>512
Ciprofloxacin
≥4
98
<1- > 128
128
>128
≥4
66
<1-64
8
32
Colistin
≥4
6
<0.25-4
2
2
≥8
0
<0.25-0.5
<0.25
0.5
Gentamicin
≥16
91
<2- > 1024
>1024
>1024
≥16
66
<2- > 1024
256
>1024
Imipenem
≥16
48
<4-128
16
32
≥8
53
<4-64
16
32
Meropenem
≥16
51
<4- > 256
32
64
≥8
53
<4-32
16
32
Piperacillin
≥128
100
<4- > 512
>512
>512
≥128
46
<4- > 512
32
256
Piperacillin/Tazobactam
≥128/4
52
<4- > 512
256
512
≥128/4
13
<4-512
32
128
aBreakpoints for antimicrobial resistance were determined according to the guidelines of the Clinical and Laboratory Standards Institute (M07-A9).
Figure 1
PFGE pattern and MLST analysis of 101Acinetobacter baumanniiisolates. Eight clusters (I-VIII) with more than 70% similarity were identified. Isolates harboring armA (●) and rmtB (○) are shown in the column on the right.
×
Of the 15 P. aeruginosa isolates, 2 had MICs >1,024 mg/L to amikacin, arbekacin and gentamicin, and harbored the 16S rRNA methylase rmtB (Figure 2). The 13 methylase-negative isolates had MICs <2 - 256 mg/L to amikacin (MIC50 64 mg/L and MIC90 128 mg/L), 1–32 mg/L to arbekacin (MIC50 2 mg/L and MIC90 4 mg/L), and 1–32 mg/L to <0.5 - 512 mg/L to gentamicin (MIC50 256 mg/L and MIC90 512 mg/L). The remaining 13 did not have any methylase genes (Figure 2).
Figure 2
PFGE pattern and MLST analysis analysis of 15Pseudomonas aeruginosaisolates. Eight clusters with more than 70% similarity were detected. Two clusters (I and II) with more than 70% similarity were identified. Isolates harboring rmtB (○) are shown in the column on the right.
×
OXAs and CTX-Ms encoding genes in 16S rRNA methylase-producing isolates
Of the 61 A. baumannii isolates harboring armA, 1 had blaOXA-23-like, blaOXA-51-like and blaCTX-Ms genes, 51 had blaOXA-23-like and blaOXA-51-like genes, and 8 had blaOXA-51-like genes. All 9 A. baumannii isolates harboring rmtB had blaOXA-23-like and blaOXA-51-like genes. In contrast, the 2 P. aeruginosa isolates harboring16S rRNA methylase genes had neither the blaOXAs nor the blaCTX-Ms gene.
PFGE analysis and MLST
PFGE analysis of the 101 A. baumannii isolates revealed 8 clusters (Figure 1). Isolates from Clusters I, III, IV, V, VI, VII, and VIII were obtained from either one or the other hospital, whereas isolates from Clusters II and III were obtained from both. These results indicate that A. baumannii isolates had expanded in a clonal manner in both hospitals and that some isolates may spread among hospitals in Vietnam.
Anzeige
The16S rRNA methylase-encoding the rmtB gene was detected in Cluster I A. baumannii isolates, whereas armA was present in isolates from Clusters I, III, IV, V, VI, VII, and VIII. Isolates harboring rmtB were obtained from one hospital and isolates harboring armA were from both hospitals.
The A. baumannii isolates producing 16S rRNA methylase belonged to ST254, ST231, ST195, ST136, ST91 and 8 new STs, ST490, ST491, ST492, ST493, ST494, ST495, ST496 and ST497 (Figure 1). Most of the A. baumannii isolates producing 16S rRNA methylase from hospital A in Hanoi were ST91 and ST231, whereas most from hospital B in Ho Chi Minh City were ST136, ST195 and ST254.
The two isolates harboring rmtB showed different patterns on PFGE, belonging to ST217 and ST313.
Genetic environment surrounding rmtB
The rmtB gene was associated with an ISCR3 mobile element upstream and a Tn3 transposon structure blaTEM-1-tnpR-tnpA downstream (data not shown). The genetic environment of rmtB had more than 99.9% nucleotide sequence identity, from nucleotide 1 to 8,337, to plasmid pXD2 (Gen bank accession no. JN315966) in E. coli, which causes bovine milk mastitis in China [12]. NCGM36, which harbored rmtB, had the blaOXA-23 and blaOXA-68 genes, but had neither the aac(6’)-Ib-cr nor the blaCTX-Ms gene.
Anzeige
Discussion
The high prevalence of 16S rRNA methylase producing Gram-negative bacteria in hospitals in Vietnam may have resulted from the high rate of use of aminoglycosides. It has been estimated that 67.4% of hospitalized patients in Vietnam received antibiotics, including 18.9% who received aminoglycosides, with many 30.8% of these prescriptions considered inappropriate [13]. This rate of antibiotic use was much higher than in European countries (17.8%-32.0%) [14, 15]. Moreover, the rate of inappropriate indications for antibiotic prescriptions in hospitals in Vietnam was much higher than rates reported in Malaysia (4.0%) [16], Turkey (14.0%) [17], and Hong Kong (20.0%) [18].
A. baumannii isolates from the northern and southern regions of Vietnam may be of different lineages. To date, 2 strains of A. baumannii showing ST91 and 3 showing ST136 have been isolated in China; 6 strains showing ST195 have been isolated, 1 in Norway, 2 in Thailand, 2 in Malaysia and 1 in China;, 5 strains showing ST231 have been isolated in Brazil and 1 strain showing ST254 has been isolated in China (http://pubmlst.org/abaumannii/). ST136 and ST195 belong to clonal complex 92, the most widely disseminated complex worldwide [19]. Two strains of P. aeruginosa producing RmtB, showing ST217 and ST313, may have originally derived from Europe or Australia, because, to date, P. aeruginosa ST217 isolates were obtained only in the United Kingdom and ST313 isolates only in Australia, France and Hungary [20] (http://pubmlst.org/paeruginosa/).
To our knowledge, this is the first report showing that A. baumannii strains harboring a 16S rRNA methylase (ArmA or RmtB) and with blaOXA-23-like and blaOXA-51-like genes are emerging in medical settings in Vietnam. ArmA and OXA-23-like producing Gram-negative pathogens have been reported in Bulgaria [21], France [22], India [23], Korea [24], Norway [25] and the United States of America [26], and ArmA and OXA-51-like producing strains have been reported in Japan [27]. Moreover, armA and rmtB have been linked to blaCTX-Ms [28, 29], but almost all ArmA producing isolates in Vietnam did not harbor blaCTX-Ms.
We found that some A. baumannii clinical isolates harbored rmtB. The genetic environment of the rmtB regions was very similar to the nucleotide sequence, from nt 1 to nt 8,337, of the plasmid pXD2. However, the plasmid of NCGM36 likely differs from pXD2 (Gen bank accession no. JN315966), in that the former NCGM36 did not have aac(6’)-Ib or blaCTX-Ms.
Anzeige
Since 16S rRNA methylase genes in A. baumannii and P. aeruginosa are located in transferable plasmids [5], the absence of methylase genes was found in the same PFGE clusters. The details of these plasmids will be reported elsewhere.
We plan to survey Gram-negative pathogens producing 16S rRNA methylases in 2013 in Vietnam, since more than 9 Gram-negative bacteria producing 16S rRNA methylases have been reported, including A. baumannii, Citrobacter freundii, Enterobacter spp (including E. cloacae), Escherichia coli, Klebsiella pneumonia, Morganella morganii, Proteus mirabilis, Providencia spp (including P. stuartii), and P. aeruginosa[5].
Conclusions
This is the first report describing the presence of methylase producing Gram-negative bacteria in medical settings in Southeast Asia, specifically in Vietnam. A. baumannii isolates from northern and southern regions of Vietnam may be of different lineages.
Acknowledgments
This study was supported by a grant (H24-Shinko-ippan-010) from the Ministry of Health, Labor and Welfare of Japan, and JSPS KAKENHI Grant Number 24790432. We thank Mrs. Kayo Shimada for PFGE analyses.
Open Access
This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License (
https://creativecommons.org/licenses/by/2.0
), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TT: Performed PCR and sequencing, analyzed data and drafted the manuscript. TMA: Performed MLST analyses. YK, NO, NT and TAT: Performed epidemiological analysis at BMH. NVH, NGB and NQA: Designed protocols and supervised this study at BMH. DMP, TTTN and PHT: Performed clinical bacterial analyses. PTX: Performed epidemiological analysis at CRH. LTAT and NTS: Designed protocols and supervised this study at CRH. TK: Designed protocols and supervised this study. All authors read and approved the final version manuscript.
Emergence of 16S rRNA methylase-producing Acinetobacter baumannii and Pseudomonas aeruginosa isolates in hospitals in Vietnam
verfasst von
Tatsuya Tada Tohru Miyoshi-Akiyama Yasuyuki Kato Norio Ohmagari Nozomi Takeshita Nguyen Viet Hung Doan Mai Phuong Truong Anh Thu Nguyen Gia Binh Nguyen Quoc Anh Tran Thi Thanh Nga Pham Hong Truong Phan Thi Xuan Le Thi Anh Thu Nguyen Truong Son Teruo Kirikae
Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.
Jeder Mensch mit Diabetes muss auf eine chronische Nierenerkrankung gescreent werden – diese neue Empfehlung spricht die KDIGO aus. Die Therapie erfolgt individuell und je nach Szenario mit verschiedenen Substanzklassen. Künftig kommt wahrscheinlich, neben RAS-Hemmung, SGLT2-Inhibition und nsMRA, eine vierte Therapiesäule hinzu.
In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.
Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
